消栓肠溶胶囊用于高血压伴高脂血症患者的临床疗效观察

Effect of Xiaosuan Enteric-coated Capsule on Hypertensive Patients with Cardiovascular Risk Factors and Its Effect on Platelet Activating Factor Content

目的:观察高血压伴心血管危险因素患者行消栓肠溶胶囊治疗的临床效果及血小板活化因子水平等相关指标的变化。方法:高血压伴高脂血症患者116例按随机数表法分2组,在常规治疗基础上,对照组(n=58)行阿司匹林肠溶片治疗,研究组(n=58)行消栓肠溶胶囊治疗。观察2组治疗前、治疗后12 w的血压[舒张压(DBP)、收缩压(SBP)]、血脂[总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)]、血小板活化因子(PAF)及血小板活化相关指标[P选择素(CD62p)、糖蛋白(GP)Ⅱb/Ⅲa受体复合物]、Framingham危险评分情况,比较随访1年内心血管不良事件(MACE)发生率。结果:治疗前2组血压、血脂指标及PAF、CD62p、GPⅡb/Ⅲa、Framingham危险评分比较差异均无统计学意义(P> 0. 05);治疗后研究组DBP、SBP、TC、LDL-C、PAF、CD62p、GPⅡb/Ⅲa水平及Framingham危险评分为(78. 24±9. 68) mm Hg、(121. 37±14. 59) mm Hg、(3. 21±0. 89) mmol/L、(2. 12±0. 68) mmol/L、(8. 54±1. 36) ng/m L、(6. 52±1. 18)%、(17. 54±2. 93)%、(4. 89±1. 13)分,均低于对照组(85. 37±9. 21) mm Hg、(133. 28±15. 19) mm Hg、(3. 97±0. 92) mmol/L、(2. 79±0. 81) mmol/L、(11. 49±2. 07) ng/m L、(9. 69±1. 58)%、(26. 37±3. 98)%、(7. 16±1. 68)分,差异有统计学意义(t=4. 064、4. 307、4. 522、4. 825、9. 071、12. 242、13. 607、8. 539,P <0. 05)。MACE总发生率研究组(3. 45%)低于对照组(13. 79%),差异有统计学意义(χ2=3. 940,P <0. 05)。结论:消栓肠溶胶囊治疗高血压伴高脂血症患者效果理想,能够显著调节血压与血脂水平,改善血小板活化程度,并有利于心血管病的防治及改善患者预后。

Objective:To explore the clinical effects of the treatment of hypertension and cardiovascular risk factors in the treatment of thrombolytic enteric capsules and changes in the levels of related indicators such as platelet activating factor.Methods:Selected 116 hypertensive patients with hyperlipidemia treated in our hospital from November 2015 to February 2017 as study subjects.According to the random number table method,the patients were divided into 2 groups.On the basis of conventional treatment,the control group(n=58)was treated with aspirin enteric-coated tablets,and the study group(n=58)was treated with Xiaosuan enteric-coated capsules.Before the 2 groups were treated,12 weeks after treatment,Observe 2 groups of blood pressure[diastolic blood pressure(DBP),systolic blood pressure(SBP)],blood lipids[total cholesterol(TC),low-density lipoprotein cholesterol(LDL-C)],and Platelet-activating factor(PAF)and markers associated with platelet activation[P-selectin(CD62p),glycoprotein(GP)IIb/IIIa receptor complex],Framingham risk score.The incidence of adverse cardiovascular events(MACE)was compared within 1 year of follow-up.Results:There was no significant difference in blood pressure,blood lipid parameters,PAF,CD62p,GPIIb/IIIa,and Framingham risk scores before treatment(P>0.05).After treatment,DBP,SBP,TC,LDL-C,PAF,CD62p,GPIIb/IIIa levels and Framingham risk scores were(78.24±9.68)mmHg,(121.37±14.59)mmHg,(3.21±0.89)mmol/L,(2.12±0.68)mmol/L,(8.54±1.36)ng/mL,(6.52±1.18)%,(17.54±2.93)%,(4.89±1.13)points,all were lower than the control group(85.37±9.21)mmHg,(133.28±15.19)mmHg,(3.97±0.92)mmol/L,(2.79±0.81)mmol/L,(11.49±2.07)ng/mL,(9.69±1.58)%,(26.37±3.98)%,(7.16±1.68)points,the difference was statistically significant(t=4.064,4.307,4.522,4.825,9.071,12.242,13.607,8.539,P<0.05).The total incidence of MACE(3.45%)was lower than the control group(13.79%),and the difference was statistically significant(χ^2=3.940,P<0.05).Conclusion:Therapeutic effect of Xiaosuan enteric-coated capsules in patients with hypertension and hyperlipidemia.It can significantly regulate blood pressure and blood lipid levels,improve platelet activation and is beneficial to the prevention and treatment of cardiovascular disease and improve patient prognosis.